Bristol Hopes REMS Proposal Can Overcome Safety Concerns About Belatacept
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's briefing documents for March 1 advisory committee review note that the kidney transplant rejection agent is linked to a potentially fatal adverse event.
You may also be interested in...
When A REMS Is Not Enough: BMS Needs More Safety Data For Belatacept
FDA's "complete response" letter for kidney transplant drug does not require that Bristol-Myers Squibb do additional clinical trials, but firm must provide updates from ongoing study before approval.
When A REMS Is Not Enough: BMS Needs More Safety Data For Belatacept
FDA's "complete response" letter for kidney transplant drug does not require that Bristol-Myers Squibb do additional clinical trials, but firm must provide updates from ongoing study before approval.
Bristol Sacrifices Part Of Indication For Kidney Transplant Drug Belatacept
Bristol-Myers Squibb is willing to tailor the patient population for its kidney transplant agent belatacept by selecting for a biomarker and limit use by recommending the less intensive treatment regimen to try and avoid the risk of post-transplant lymphoproliferative disorder that was seen in clinical trials